--- title: Low Concentrate Detergents Versus Hypertonic Glucose for the Treatment of Telangiectasia nct_id: NCT04132323 overall_status: COMPLETED phase: NA sponsor: Derzhavin Tambov State University study_type: INTERVENTIONAL primary_condition: Sclerotherapy countries: Russia canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04132323.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04132323" ct_last_update_post_date: 2023-10-10 last_seen_at: "2026-05-12T06:12:01.285Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Low Concentrate Detergents Versus Hypertonic Glucose for the Treatment of Telangiectasia **Official Title:** Clinical Efficacy of Low Concentrate Detergents Versus Hypertonic Glucose for the Treatment of Telangiectasia: a Prospective Randomized Clinical Trial **NCT ID:** [NCT04132323](https://clinicaltrials.gov/study/NCT04132323) ## Key Facts - **Status:** COMPLETED - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 172 - **Lead Sponsor:** Derzhavin Tambov State University - **Conditions:** Sclerotherapy - **Start Date:** 2019-10-25 - **Completion Date:** 2022-03-15 - **CT.gov Last Update:** 2023-10-10 ## Brief Summary Using of low concentrate sodium tetradecyl sulfate for sclerotherapy of telangiectasias should be no less effective than hypertonic glucose, and have a comparable frequency of adverse events. ## Detailed Description For sclerotherapy of telangiectasias are used detergents. These are aggressive substances, which have a high frequency of adverse events. According to histological studies the safest concentration for the treatment of telangiectasias is less than that specified in the official instructions. The concentration of sodium tetradecyl sulfate 0.15% was effective and did not cause any adverse reactions in the treatment of telangiectasias from 0.8 to 1 mm in diameter. Small telangiectases (0.5 mm or less) require the treatment with the less aggressive sclerosing agent. Perhaps, the sodium tetradecyl sulfate 0.15%, 0.1% or even 0.05% and hypertonic glucose may be more effective and safe in this situation. ## Eligibility - **Sex:** FEMALE - **Healthy Volunteers:** No ``` Inclusion Criteria: * women over 18 * single primary or secondary telangiectasias unrelated to the reticular veins * signed informed consent to participate in the study Exclusion Criteria: * telangiectasias associated with reticular veins * diabetes mellitus * pregnancy or lactation * malignant neoplasms * inability or unwillingness of the patient to wear compression stockings * hypersensitivity to one of the drugs * concomitant diseases: bronchial asthma, severe liver and kidney disease, acute thrombosis and thrombophlebitis, infection of the skin and/or soft tissues, infectious diseases, arteriosclerosis, diabetic angiopathy, heart defects requiring surgery, fever, toxic hyperthyroidism, obesity, tuberculosis, sepsis, violation of the cellular composition of the blood, all diseases requiring bed rest, heart disease with decompensation phenomena, known hereditary thrombophilia. * period after treatment of alcoholism * reception of oral contraceptives * sedentary lifestyle ``` ## Arms - **hypertonic glucose** (ACTIVE_COMPARATOR) — * to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm. * to measure the maximum diameter of telangiectasia using the Dermatoscope scale. * to inject the 75% glucose, with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears. - **0.05% sodium tetradecyl sulfate** (ACTIVE_COMPARATOR) — * to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm. * to measure the maximum diameter of telangiectasia using the Dermatoscope scale. * to inject the 0.05% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears. - **0.1% sodium tetradecyl sulfate** (ACTIVE_COMPARATOR) — * to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm. * to measure the maximum diameter of telangiectasia using the Dermatoscope scale. * to inject the 0.1% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears. - **0.15% sodium tetradecyl sulfate** (ACTIVE_COMPARATOR) — * to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm. * to measure the maximum diameter of telangiectasia using the Dermatoscope scale. * to inject the 0.15% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears. ## Interventions - **Sclerotherapy** (PROCEDURE) — Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy according to the randomization group ## Primary Outcomes - **Disappearance of the telangiectasia** _(time frame: 2 months)_ — The clearing of the vessels on the six-point scale (from 0 to 5 points): 5 - total disappearance of the matting (100% efficacy), 4 - disappearance of around 80%, 3 - disappearance of around 60%, 2 - disappearance of around 40%, 1 - disappearance of around 20%, 0 - no changes. ## Secondary Outcomes - **Pain during the procedure: visual analog scale** _(time frame: immediately after the procedure)_ - **Patient Satisfaction After Treatment** _(time frame: 2 months)_ ## Locations (1) - Bukina Oksana Vasilyevna, Tambov, Russia ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.bukina oksana vasilyevna|tambov||russia` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT04132323.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT04132323* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*